Institutional members access full text with Ovid®

Share this article on:

A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease

Ramírez Gómez, Carolina Candelaria MD; Serrano Dueñas, Marcos MD; Bernal, Oscar MD; Araoz, Natalia MD; Sáenz Farret, Michel MD; Aldinio, Victoria MD; Montilla, Verónica MD; Micheli, Federico MD, PhD

doi: 10.1097/WNF.0000000000000202
Original Articles

Objectives: Impulse control disorder (ICD) is a common adverse effect in patients with Parkinson disease who receive dopamine agonists; however, other factors are involved in its manifestations. To study the frequency and factors involved in the development of this adverse effect in a Latin American population, we conducted a cross-sectional multicenter study.

Methods: Two hundred fifty-five patients in 3 Latin American centers were evaluated by examination and application of scales (Unified Parkinson’s Disease Rating Scale, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale, Hoehn and Yahr, Clinical Impression of Severity Index for Parkinson’s Disease).

Results: Of the patients, 27.4% had ICD, most of whom were on dopamine agonists. Other associated risk factors included a younger age at onset of Parkinson disease, moderate symptoms, a shorter evolution of the clinical manifestations, rapid eye movement (REM) sleep disorder behavior, and the consumption of tea, mate, and alcohol.

Conclusions: The frequency of ICD is higher in Latin America than in Anglo-Saxon populations. Consuming tea and mate, in addition to the use of dopamine agonists, is a factor that may demonstrate a genetic link that predisposes patients to the establishment of an ICD.

*Parkinson’s Disease and Movement Disorder Unit, Hospital de Clínicas “José de San Martín,” School of Medicine, University of Buenos Aires, Buenos Aires, Argentina; †School of Medicine, Pontifical Catholic University of Ecuador, and Neurological Unit, “Carlos Andrade Marín” Hospital, Quito, Ecuador; and ‡Nueva Granada Military University, Military Hospital, Santa Fe de Bogotá Foundation, Bogotá, Colombia.

Address correspondence and reprint requests to Federico Micheli, MD, PhD, Juncal 1695 5J, 1062, C.A.B.A., Argentina; E-mail: fmicheli@fibertel.com.ar

Conflicts of Interest and Source of Funding: F.M. received honoraria from Eli Lilly, Allergan, Boehriger Ingelheim, Novartis, UCB, Merz, and Viguera. The other authors have no conflicts of interest to declare.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.